GILD Archives - Page 18 of 29

2 minute read

Wall Street’s Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields

March 27, 9:27 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

AMGN

1 minute read

Bunge, Gilead Sciences And A Famous Chocolate Maker On CNBC’s ‘Final Trades’

By Priya Nigam

March 27, 8:34 AM

On CNBC’s "Halftime Report Final Trades," JP Morgan Private Bank’s Anastasia Amoroso said she is sticking with Invesco QQQ Tru

1 minute read

Gilead Exercises First License Option Under Agreement With Nurix Therapeutics

By Vandana Singh

March 20, 10:17 AM

Gilead Sciences Inc (NASDAQ:GILD) has exercised its option to license Nurix Therapeutics Inc’s (NASDAQ:NRIX) investigational targeted protein degrader molecule NX-0479 exclusively. This…

GILD

2 minute read

Gilead Sciences Unusual Options Activity

By Benzinga Insights

March 17, 2:45 PM

Someone with a lot of money to spend has taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And…

GILD

2 minute read

Peering Into Gilead Sciences’s Recent Short Interest

By Benzinga Insights

March 6, 11:45 AM

Gilead Sciences’s (NASDAQ:GILD) short percent of float has risen 3.28% since its last report. The company recently reported…

GILD

1 minute read

GSK/Pfizer-Backed ViiV Healthcare’s HIV Treatment At Par With Gilead’s: Study Shows

By Vandana Singh

February 23, 9:43 AM

ViiV Healthcare, majority-owned by GSK Plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited, announced 12-month findings from the SOLAR Phase 3b study of the long-acting injectable…

GILD

3 minute read

Gilead Presents Proof-Of-Concept Data For Investigational Combination Regimen Of Lenacapavir With Broadly Neutralizing Antibodies As A Potential Twice-Yearly Approach For The Treatment Of HIV

By Happy Mohamed

February 22, 12:22 PM

– Study Demonstrates the Potential of Lenacapavir in Combination with Broadly Neutralizing HIV Antibodies Teropavimab and Zinlirvimab – – Findings Support Further Evaluation of the Investigational

GILD

1 minute read

If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today

By Benzinga Insights

February 17, 3:02 PM

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 8.18% on an annualized basis…

GILD

3 minute read

Trodelvy Demonstrates Efficacy Treating Both Platinum-Ineligible And Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer

By Happy Mohamed

February 17, 10:01 AM

– Oral Presentation Highlights Trodelvy Efficacy of 13.5 Months Overall Survival in Patients with Platinum-Ineligible Metastatic UC After Checkpoint Inhibitor Therapy – – Trodelvy Demonstrated

GILD

1 minute read

FDA
News

Gilead Highlights Kite’s Tecartus CAR T-Cell Therapy Data In 3-Year Follow-Up Of Pivotal ZUMA-3 Trial

By Benzinga Newsdesk

February 9, 8:33 AM

-- In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months --

GILD

Feed Symbols: GILD